Metoprolol tartrate and hydrochlorothiazide

Metoprolol tartrate and hydrochlorothiazide is filed as Thiazide Diuretic [EPC]. The sections below restate public label fields stored for this profile.

Class
Thiazide Diuretic [EPC]
Route
ORAL
Dosage forms
Abrupt cessation may exacerbate myocardial ischemia. ( 5.1 ) May worsen congestive heart failure. ( 5.2 ) Bronchospasm: Avoid beta-blockers. ( 5.3 ) Bradycardia. ( 5.4 ) Avoid discontinuing therapy prior to major surgery. ( 5.5 ) Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor. ( 5.6 ) Monitor serum electrolytes and creatinine periodically. ( 5.7 ) Peripheral vascular disease: Can aggravate symptoms of arterial insufficiency. ( 5.9 ) Pheochromocytoma: First initiate therapy with an alpha blocker. ( 5.10 ) Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. ( 5.11 ) Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. ( 5.12 )
Generic available
Yes
Manufacturer
Alembic Pharmaceuticals Inc.

Approved uses

Metoprolol tartrate and hydrochlorothiazide tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components.

How it works

Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocker. This preferential effect is not absolute however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of renin activity. The mechanism of antihypertensive effect of thiazide diuretics is unknown.

Warnings and precautions

WARNINGS Metoprolol Cardiac Failure: Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn. Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and in some cases, myocardial infarction have been reported. Even in the absence of overt angina pectoris, when discontinuing therapy, metoprolol should not be withdrawn abruptly, and patients should be cautioned against interruption of therapy without the physician’s advice (see PRECAUTIONS: Information for Patients). Bronchospastic Diseases: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS, including metoprolol tartrate and hydrochlorothiazide. Because of its relative beta 1 selectivity, however, metoprolol may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since beta 1 selectivity is not absolute, a beta 2 -stimulating agent should be administered concomitantly, and the lowest possible dose of metoprolol should be used. In these circumstances it would be prudent initially to administer metoprolol in smaller doses three times daily, instead of larger doses two times daily, to avoid the higher plasma levels associated with the longer dosing interval (see DOSAGE AND ADMINISTRATION). Major Surgery: Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Diabetes and Hypoglycemia: Metoprolol should be used with caution in diabetic patients if a beta-blocking agent is required. Beta blockers, including metoprolol tartrate and hydrochlorothiazide, may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected. Selective beta blockers do not potentiate insulin-induced hypoglycemia and, unlike nonselective beta blockers, do not delay recovery of blood glucose to normal levels. Pheochromocytoma: If metoprolol tartrate is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle. Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) or hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta blockade, which might precipitate a thyroid storm. Hydrochlorothiazide Thiazides should be used with caution in patients with severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte imbalance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs. Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Acute Myopia and Secondary Angle-Closure Glaucoma: Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

Contraindications

Metoprolol tartrate and hydrochlorothiazide tablets is contraindicated in patients with: Cardiogenic shock or decompensated heart failure . Sinus bradycardia, sick sinus syndrome, and greater than first-degree block unless a permanent pacemaker is in place . Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs.

Adverse reactions

The following adverse reactions are described in more detail elsewhere in the label; Worsening angina or myocardial infarction [see Warnings and Precautions ( 5 )] Worsening heart failure [see Warnings and Precautions ( 5 )] Worsening AV block [see Contraindications ( 4 )]

Dosage and administration

Usual dose range: Hydrochlorothiazide 12.5 to 25 mg and metoprolol tartrate 100 mg dosed once daily. ( 2.1 )

Drug interactions

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. ( 7.1 ) CYP2D6 inhibitors: Increased metoprolol concentration. ( 12.3 ) Digitalis glycosides, clonidine, diltiazem and verapamil: Bradycardia. ( 5.4 , 7.1 ) Clonidine: Rebound hypertension following clonidine withdrawal. ( 7.1 ) Antidiabetic drugs: Dosage adjustment may be required. ( 7.2 ) Cholestyramine and colestipol: Reduced absorption of thiazides. ( 7.2 ) Lithium: Risk of lithium toxicity. ( 7.2 ) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. ( 7.2 )

Common questions

What is Metoprolol tartrate and hydrochlorothiazide approved to treat?

According to its FDA label, Metoprolol tartrate and hydrochlorothiazide is approved for: Metoprolol tartrate and hydrochlorothiazide tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have bee… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Metoprolol tartrate and hydrochlorothiazide?

Metoprolol tartrate and hydrochlorothiazide belongs to the Thiazide Diuretic [EPC] class of medications.

What form does Metoprolol tartrate and hydrochlorothiazide come in?

The FDA label lists Metoprolol tartrate and hydrochlorothiazide as: Abrupt cessation may exacerbate myocardial ischemia. ( 5.1 ) May worsen congestive heart failure. ( 5.2 ) Bronchospasm: Avoid beta-blockers. ( 5.3 ) Bradycardia. ( 5.4 ) Avoid discontinuing therapy prior to major surgery. ( 5.5 ) Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor. ( 5.6 ) Monitor serum electrolytes and creatinine periodically. ( 5.7 ) Peripheral vascular disease: Can aggravate symptoms of arterial insufficiency. ( 5.9 ) Pheochromocytoma: First initiate therapy with an alpha blocker. ( 5.10 ) Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. ( 5.11 ) Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. ( 5.12 ); oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Metoprolol tartrate and hydrochlorothiazide?

Yes. A generic version of Metoprolol tartrate and hydrochlorothiazide is available in the U.S. Ask your pharmacist about substitution.

Does Metoprolol tartrate and hydrochlorothiazide have a Boxed Warning?

Our ingest of the FDA label for Metoprolol tartrate and hydrochlorothiazide does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Metoprolol tartrate and hydrochlorothiazide currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Metoprolol tartrate and hydrochlorothiazide in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Metoprolol tartrate and hydrochlorothiazide approved by the FDA?

The FDA record lists the approval date for Metoprolol tartrate and hydrochlorothiazide as 2013-11-06.

Who makes Metoprolol tartrate and hydrochlorothiazide?

The FDA label lists Alembic Pharmaceuticals Inc. as a labeler/manufacturer of Metoprolol tartrate and hydrochlorothiazide. Multiple firms may market generics of the same molecule.

How should Metoprolol tartrate and hydrochlorothiazide be stored?

The FDA label states: "50 mg/25 mg tablets are white to off white, round shaped, biconvex, bevel edged scored uncoated tablets de bossed with "A" on one side of score line and "47" on another side of score line and plain on other side. NDC 272…" Follow the packaging insert for the authoritative guidance.

What is the pregnancy category for Metoprolol tartrate and hydrochlorothiazide?

The FDA label lists a pregnancy category of C for Metoprolol tartrate and hydrochlorothiazide. Pregnancy and lactation decisions should be made with a clinician.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…